"Exhaled Breath Condensate" in Allogeneic Stem Cell Recipients and the Value in Follow-up
- Conditions
- Exhaled Breath Condensate
- Interventions
- Other: Exhaled breath condensate
- Registration Number
- NCT02318316
- Lead Sponsor
- Gazi University
- Brief Summary
The most effective treatment of hematologic malignancies and some benign hematological diseases is allogeneic stem cell transplantation therapy. Pulmonary complications can occur after allogeneic stem cell transplantation. And these complications effect mortality and morbidity in these patients. In this study we want to investigate the use of exhaled breath condensate (EBC) collection which is a simple and completely noninvasive method. By this way we hope to detect pulmonary complications early. EBC, has been implicated in the pathophysiology of inflammatory airway diseases such as cystic fibrosis, asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis. EBC, has not been investigated before in patients who underwent stem cell transplantation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 80
- hematologic malignancies or benign hematological diseases that allogeneic stem cell transplantation performed
- allogeneic stem cell transplantation patients with Asthma or COPD
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description EBC level Exhaled breath condensate Exhaled breath condensate level of allogeneic stem cell transplantation patients
- Primary Outcome Measures
Name Time Method The pH level of exhaled breath condansate 2 years
- Secondary Outcome Measures
Name Time Method The nitrotyrosine and 8-isoprostane levels of exhaled breath condansate 2 years